Gilenya
(fingolimod) Novartis

Composition:
• Available in hard capsule with each contains 0.25 mg or 0.5 mg fingolimod for oral administration

Indication:
• As single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult patients and paediatric patients aged 10 years and older:

　　• Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy

　　• Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI

Drug information including formulation, indication, administration and/or presentation updated, registered or launched in Hong Kong within one year prior to the date written is regarded as new in The Pace.
The information in The Pace is provided as a courtesy service to our readers and is intended for medical professional reference only. Please peruse the latest local prescription information prior to prescription.